Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Apr 14, 2020 6:50am
190 Views
Post# 30906256

More to come for sure

More to come for sureI felt had to happen..there was still alot left up in the air and unanswered questions... I think the stero deal was last minute surprise to show an interested party that kly was not happy with their offer ... even or multiples still interested... Echelon still indicated after the stero deal price anticipation still .30 cents ...and as well there was no mention how we were paying them for services...with no sign of the voting process administered...this had to be addressed at this point... when Rob said everything was on hold with the rest of the pipeline products .... even update on the FDA approval .... let's see what is coming but it has to be better then buying Stero at the deal we were... I believe stero has value but Kly really wasn't in a good position...maybe possible kly and stero will be part of a package deal ... it has been super quiet with no info leaked...the stero purchase was a complete shock for most ...hold tight and glta
<< Previous
Bullboard Posts
Next >>